Biotech News

Cue Biopharma Reports Third Quarter 2026 Financial Results and Recent Business Highlights

Cue Biopharma Inc (CUE)Cue Biopharma IncEarnings

Cue Biopharma, Inc. (Nasdaq: CUE), a clinical stage biopharmaceutical company targeting transformative therapies for immune-mediated diseases, today reported third quarter 2026 financial results as well as recent business highlights.

Related news

Cue Biopharma Inc

Immune-Mediated Disease Portfolio Cue Biopharma is a clinical-stage biotechnology company developing therapies for allergic and autoimmune diseases. Its portfolio combines a conventional antibody program with an Immuno-STAT platform designed to selectively regulate disease-driving immune cells. CUE-221 CUE-221 is a dual-mechanism...

Recent company news

Stock data

Close
4.50 USD
Market cap
115.79M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States